HighTide Therapeutics

Recent Finacing

Series C+

Recent Raise

$107M

HighTide Therapeutics is a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, advancing lead candidate HTD1801 in clinical trials for T2DM, NASH, SHTG, and PSC.

Founded 2011

Guangdong, China

51-100

Publicly Traded

hightidetx.com

Highlights

Focus Areas

Biopharma

Biotechnology

Health Care

Recent Investors

T

Y

Financials

$107M

Total Raised

1

Funding round

3

Investors

Team

Upgrade to view the team

See the team members at HighTide Therapeutics.